tamivarotene
Urothelial Carcinoma Urethra
Nagoya UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Urothelial Carcinoma Urethra cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Nagoya University | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University | Phase 3 | BB |
Pembrolizumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Cyclophosphamide Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Relatlimab National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 23 →
Same molecule, other indications
tamivarotene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →